Eli Lilly and Company (NYSE:LLY) is one of the top S&P 500 stocks by index weight. On April 15, BMO Capital reiterated an ...

Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Eli Lilly (NYSE:LLY) reported positive phase 3 ACHIEVE-4 results for its once-daily oral GLP-1 therapy Foundayo (orforglipron ...

The pharmaceutical’s Foundayo drug takes on oral Wegovy, the popular treatment from Novo Nordisk.

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

The results seen with Foundayo, also known as orforglipron, enabled Lilly’s late-stage Achieve-4 study to hit its primary ...

"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be ...

While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital ...

On April 15, 2026, Eli Lilly and Company (NYSE:LLY) reported topline results from the Phase 3 ACHIEVE-4 trial evaluating ...

The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly’s expansion into cancer treatments.